Impact of Phosphodiesterase-5 Inhibitor Treatment Delay on Secondary Raynaud’s Phenomenon Outcomes

Mendeley Data 2026 Dataset Open access

Read full text
Authors: Isabella Zappi, Derek Maas, Michelle Sikora, Archie J. Spindler, Ambika Nohria, Deesha D. Desai, Chinemelum Obijiofor, Mark Richardson, Jerry Shapiro, Alisa N. Femia, Amit Saxena, Avrom S. Caplan
+2 more Daniel R. Mazori, Kristen I. Lo Sicco
DOI: 10.17632/tbs4zb2vdv
Cited by: 0

Abstract

This dataset includes information collected from patient with secondary Raynaud's phenomenon treated with phosphodiesterase-5 inhibitors. Demographic infromation, secondary Raynaud's phenomenon characteristics, and phosphodiesterase-5 inhibitor effects determined by physician and/or patient reports were collected. Multivariate logistic regression assessed associations with adverse outcomes using RStudio (α=0.05).

Fields of Study & Subjects

Systemic Sclerosis and Related Diseases Pulmonary Hypertension Research and Treatments Sexual function and dysfunction studies

Publication details

Journal / source
Mendeley Data
Publication date
15 January 2026
Document type
Dataset